CJC-1295
CJC-1295 is a synthetic version of growth-hormone-releasing hormone. Small early studies showed it raises growth hormone and IGF-1, but it was never approved and development stopped.
What it is
A modified GHRH analog that signals the pituitary gland to release more growth hormone.
What the evidence shows
In people
Small pharmacology studies in healthy adults showed sustained increases in growth hormone and IGF-1. No outcome trials show benefits for body composition or health.
In animals and labs
Animal work supports the mechanism.
Legal status
Not FDA-approved. Prohibited in sport as a growth hormone releasing factor.
Dosing
There is no established human dose
No regulator has approved a dose for human use. Numbers shared online come from animal studies, small early trials, or seller protocols, and none of them have been shown to be safe or effective. BOTH does not publish dosing, mixing, or injection instructions for unapproved compounds.
Known risks
- Water retention, joint pain, and numbness or tingling linked to raised growth hormone
- Possible effects on blood sugar
- Unknown long-term effects of raising IGF-1
- Contamination and mislabeling in research-grade products
Read our in-depth article on CJC-1295 →